CA2012631A1 - Procede de production d'anticorps hetero-bispecifiques - Google Patents

Procede de production d'anticorps hetero-bispecifiques

Info

Publication number
CA2012631A1
CA2012631A1 CA2012631A CA2012631A CA2012631A1 CA 2012631 A1 CA2012631 A1 CA 2012631A1 CA 2012631 A CA2012631 A CA 2012631A CA 2012631 A CA2012631 A CA 2012631A CA 2012631 A1 CA2012631 A1 CA 2012631A1
Authority
CA
Canada
Prior art keywords
hetero
production
cell line
antibodies
bispecific antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2012631A
Other languages
English (en)
Other versions
CA2012631C (fr
Inventor
Helmut Lenz
Ulrich Weidle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of CA2012631A1 publication Critical patent/CA2012631A1/fr
Application granted granted Critical
Publication of CA2012631C publication Critical patent/CA2012631C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/972Modified antibody, e.g. hybrid, bifunctional

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA002012631A 1989-03-23 1990-03-20 Procede de production d'anticorps hetero-bispecifiques Expired - Lifetime CA2012631C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3909708A DE3909708A1 (de) 1989-03-23 1989-03-23 Verfahren zur herstellung bispezifischer antikoerper
DEP3909708.0 1989-03-23

Publications (2)

Publication Number Publication Date
CA2012631A1 true CA2012631A1 (fr) 1990-09-23
CA2012631C CA2012631C (fr) 1995-03-28

Family

ID=6377122

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002012631A Expired - Lifetime CA2012631C (fr) 1989-03-23 1990-03-20 Procede de production d'anticorps hetero-bispecifiques

Country Status (6)

Country Link
US (1) US6060285A (fr)
EP (1) EP0388964B1 (fr)
JP (1) JPH0716436B2 (fr)
AT (1) ATE113659T1 (fr)
CA (1) CA2012631C (fr)
DE (2) DE3909708A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2066720A1 (fr) * 1989-09-19 1991-03-20 David M. Knight Methode d'amelioration de la production d'anticorps monoclonaux humains
TW212184B (fr) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US20020155109A1 (en) * 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
PT2308888T (pt) 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
JP2007500132A (ja) 2003-07-25 2007-01-11 アムジェン インコーポレイテッド Ldcamのアンタゴニストおよびアゴニスト、並びにその使用法
WO2005077065A2 (fr) * 2004-02-09 2005-08-25 The Regents Of The University Of California Ligands polyvalents selectifs a haute affinite et methodes de fabrication
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
WO2007005955A2 (fr) 2005-06-30 2007-01-11 Centocor, Inc. Anticorps anti-il-23, compositions, methodes et utilisations
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
CA2646478A1 (fr) 2006-03-10 2007-09-20 Zymogenetics, Inc. Anticorps se liant a la fois avec il-17a et il-17f et procedes d'utilisation
WO2008140493A2 (fr) * 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anticorps de la famille anti-egfr, anticorps de la famille anti-egfr bispécifiques et leurs procédés d'utilisation
AU2007352412B2 (en) 2007-04-27 2013-05-16 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
ES2613844T3 (es) 2008-04-21 2017-05-26 Lawrence Livermore National Security, Llc Ligandos polidentados de alta afinidad selectivos y métodos para producirlos
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
MX341687B (es) 2010-02-10 2016-08-30 Immunogen Inc "anticuerpos cd20 y su utilización".
PL2552961T3 (pl) 2010-03-30 2018-04-30 Janssen Biotech, Inc. Humanizowane przeciwciała il-25
US20130101590A1 (en) 2010-04-09 2013-04-25 Heather A. Arnett Btnl9 proteins, nucleic acids, and antibodies and uses thereof
EP4269563A3 (fr) 2010-06-19 2024-01-10 Memorial Sloan-Kettering Cancer Center Anticorps anti-gd2
CN104703999A (zh) 2012-07-19 2015-06-10 安姆根有限公司 人btnl3蛋白、核酸和抗体及其用途
JP6482525B2 (ja) 2013-03-15 2019-03-13 メモリアル スローン ケタリング キャンサー センター 高親和性抗gd2抗体
WO2014190316A1 (fr) 2013-05-23 2014-11-27 Shire Human Genetic Therapies, Inc. Thérapie combinatoire anti-ccl2 et anti-loxl2 pour le traitement de la sclérodermie
ES2920677T3 (es) 2013-12-24 2022-08-08 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-VISTA
JP6386329B2 (ja) 2014-10-06 2018-09-05 テイ・エス テック株式会社 車両用シートの表皮材
FI3447075T3 (fi) 2015-05-15 2023-11-07 Massachusetts Gen Hospital Antagonistisia anti-tuumorinekroositekijäreseptorin superperheen vasta-aineita
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
TWI756204B (zh) 2016-02-12 2022-03-01 比利時商楊森製藥公司 抗vista抗體及片段、其用途及鑑定其之方法
BR112018069776A2 (pt) 2016-03-29 2019-02-05 Janssen Biotech Inc tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23
WO2017175058A1 (fr) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anticorps anti-vista et fragments de ceux-ci, leurs utilisations et leurs procédés d'identification
US11534496B2 (en) 2016-06-07 2022-12-27 The Brigham And Women's Hospital, Inc. Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
AU2017321973A1 (en) 2016-09-02 2019-03-07 Dana-Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
KR20190059305A (ko) 2016-09-30 2019-05-30 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
AU2017362222A1 (en) 2016-11-16 2019-05-30 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL-23 specific antibody
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
JP2020506947A (ja) 2017-02-07 2020-03-05 ヤンセン バイオテツク,インコーポレーテツド 活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
EP3790587A4 (fr) 2018-05-11 2022-01-26 Janssen Biotech, Inc. Méthodes de traitement de la dépression à l'aide d'anticorps il-23
CN112805381A (zh) 2018-06-21 2021-05-14 优曼尼蒂治疗公司 用于治疗和预防神经病症的组合物和方法
WO2020014306A1 (fr) 2018-07-10 2020-01-16 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
JP2021530697A (ja) 2018-07-18 2021-11-11 ヤンセン バイオテツク,インコーポレーテツド 抗il23特異的抗体で治療した後の持続応答予測因子
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
BR112021023295A2 (pt) 2019-05-23 2022-02-08 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
KR20220030952A (ko) 2019-06-03 2022-03-11 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2021028752A1 (fr) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anticorps anti-tfn pour le traitement du diabète de type i
JP2024510588A (ja) 2021-03-12 2024-03-08 ヤンセン バイオテツク,インコーポレーテツド 抗il23特異的抗体による、tnf療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
US20220298236A1 (en) 2021-03-12 2022-09-22 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
WO2023073615A1 (fr) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2023095000A1 (fr) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Méthode de traitement de la rectocolite hémorragique avec un anticorps spécifique anti-il23
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
WO2023215498A2 (fr) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions et procédés pour un antagonisme de cd28
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
WO2024097639A1 (fr) 2022-10-31 2024-05-10 Modernatx, Inc. Anticorps se liant à hsa et protéines de liaison et leurs utilisations
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2024118866A1 (fr) 2022-12-01 2024-06-06 Modernatx, Inc. Anticorps spécifiques au gpc3, domaines de liaison, protéines associées et leurs utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Also Published As

Publication number Publication date
US6060285A (en) 2000-05-09
JPH0335800A (ja) 1991-02-15
EP0388964B1 (fr) 1994-11-02
DE3909708A1 (de) 1990-09-27
ATE113659T1 (de) 1994-11-15
CA2012631C (fr) 1995-03-28
DE59007589D1 (de) 1994-12-08
EP0388964A2 (fr) 1990-09-26
JPH0716436B2 (ja) 1995-03-01
EP0388964A3 (fr) 1991-03-27

Similar Documents

Publication Publication Date Title
CA2012631A1 (fr) Procede de production d'anticorps hetero-bispecifiques
US4714681A (en) Quadroma cells and trioma cells and methods for the production of same
EP0068763B2 (fr) Anticorps monoclonaux recombinants
EP1167537A4 (fr) Procede pour la production d'anticorps monoclonal
AU577745B2 (en) Somatic human hybridoma fusion partner for the production of human monoclonal antibodies
AU8817391A (en) Method for the production of antibodies
CA2508763A1 (fr) Souris produisant des anticorps humains et procede de production d'anticorps humains
ATE176926T1 (de) Antikörperherstellung
AU542303B2 (en) Antibody production by rat myeloma cells
AU1582495A (en) Recombinant baculovirus and use thereof in the production of monoclonal antibodies
PT1695985E (pt) Métodos para formar anticorpos humanizados por mutagénese aleatória
CA2234931A1 (fr) Nouveaux vecteurs d'expression et procedes d'utilisation correspondants
LU91320I2 (fr) "Ranibizumab et ses dérivés pharmaceutiquement acceptables (LUCENTIS )"
MXPA04004634A (es) Expresion policistronica de anticuerpos.
EP0335573A3 (fr) Procédé de préparation de 2'''-0-demethyltylosin
AU545181B2 (en) Hybridoma for producing monoclonal antibodies
AU579628B2 (en) Method of isolating monoclonal antibodies from hybridoma cultures
ATE217888T1 (de) Monoklonale antikörper gegen leukozyten- spezifische g-protein-gekoppelte rezeptoren
CA2263790A1 (fr) Methode permettant d'immortaliser des cellules
Trejdosiewicz et al. Monoclonal antibodies to human urothelial cell lines and hybrids: production and characterization
WO1994011507A3 (fr) Production d'anticorps monoclonaux recombines sans utilisation d'hybridomes et par culture in vitro de fragment de rate combinee avec la replication autonome isothermique de sequences d'arn
Neuberger et al. Protein engineering of antibody molecules
AU669947B2 (en) Process for preparing recombinant and synthetic peptides, and their use
WO1996033279A3 (fr) Procede de clonage de repertoires, produits derives de ce dernier et utilisations desdits produits
EP0346702A3 (fr) Lignées cellulaires transfectées exprimant des gènes isolés appartenant à la famille de l'antigène carcinoembryonnaire

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry